

Baxter Healthcare – Novel Coronavirus (COVID-19) – Operations Update

Dear Baxter Healthcare customer

Please see below the latest information about Baxter Healthcare operations in response to the Novel Coronavirus (COVID-19) in Australia.

As you are aware, the Australian Federal Government has announced a formal health sector emergency response plan for COVID-19.

Baxter is currently working closely with public and private hospitals across Australia to meet increasing demand for Baxter products and assisting customers and Governments with inventory management and pandemic preparations.

There is currently no impact from COVID-19 to Baxter manufacturing operations in Australia and no impact to supply of Baxter products manufactured outside of Australia. This includes the supply of Baxter surgical care products, infusion systems, PD and HD dialysis products and acute therapies products for the ICU.

Baxter is in contact with the Therapeutic Goods Administration of Australia and will advise customers immediately of any changes to supply.

Please see below further updates on Baxter Healthcare's local manufacturing and pharmaceutical compounding operations, increased support for Hospital-in-the-Home services and implementation of Baxter ICNET infection and outbreak management systems for hospitals.

Local manufacture and compounding operations

As one of Australia's largest healthcare companies, Baxter is well-placed to assist hospitals and State and Federal Governments in response to the coronavirus outbreak.

Baxter is the largest and only local manufacturer of IV products and peritoneal dialysis fluids in Australia and operates the largest TGA-licensed aseptic compounding network in Australia with facilities in all mainland states.

Our local operations include the manufacture of IV fluids and PD dialysis fluids at our local Baxter manufacturing facility in Western Sydney, as well as pharmaceutical compounding of chemotherapy, analgesics, antibiotics, IV additives and parenteral nutrition.

For more information about Baxter IV fluids please contact David Dal Pos
david_dal_pos@baxter.com

Baxter Healthcare Head Office and Customer Service are also located in Western Sydney with local offices and warehouse facilities in all mainland states.

Baxter has applied Global EH&S Stringent & Disciplined anti-pandemic measures to its operations in Australia as part of its local pandemic action plan. This includes the monitoring of employee health, enhanced hygiene protocols and self-quarantining of employees with cold or flu like symptoms.

Hospital-in-the-Home services

Baxter is working closely with local healthcare services to meet an increase in demand for Hospital-in-the-Home services across Australia.

Baxter pharmaceutical compounding facilities in all mainland states in Australia prepare and supply patient-specific formulations of antibiotic, parenteral nutrition and chemotherapy treatment in the home.

There is currently no impact to the supply of Baxter drug infusor devices for Hospital-in-the-Home therapies and Baxter is managing its national network of compounding facilities to support customers and Governments with treatments carried out in the home.

For more information about support for Hospital-in-the-Home services please contact Sai Sridar on +61428836235

Infection and outbreak management systems

Baxter is working with hospitals in Australia to implement ICNET Clinical Surveillance System for detecting and managing infection outbreaks in hospitals.

The outbreak of novel coronavirus (COVID-19) is now captured as part of the ICNET functionality.

Baxter Digital Health team is currently supporting hospitals in Australia with the updated functionality and ongoing operation of ICNET software.

There is currently no impact to ICNET software or Baxter Digital Health services in Australia.

For more information about ICNET for hospitals please contact Danny Hird
daniel_hird@baxter.com

Intensive Care Unit support

Baxter is working with hospitals in Australia to manage demand for acute therapies products for Intensive Care Units.

There is currently no impact to supply of Baxter Continuous Renal Replacement Therapy products.

Global supply chain

Baxter continues to monitor its international supply chain closely in response to the COVID-19.

There are currently no supply shortages as a result of coronavirus and no immediate risk to raw material or Baxter medical devices manufactured globally.

There are no Baxter manufacturing facilities in Wuhan Province, China, and all Baxter manufacturing operations outside of Australia are currently in operation.

For more information about the manufacture and supply of Baxter products and services please contact Australia_SHS_Customer_Support@baxter.com